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Abstract 
Background: 4‑Hydroxymandelic acid (4‑HMA) is a valuable aromatic fine chemical and widely used for production 
of pharmaceuticals and food additives. 4‑HMA is conventionally synthesized by chemical condensation of glyoxylic 
acid with excessive phenol, and the process is environmentally unfriendly. Microbial cell factory would be an attrac‑
tive approach for 4‑HMA production from renewable and sustainable resources.
Results: In this study, a biosynthetic pathway for 4‑HMA production was constructed by heterologously expressing 
the fully synthetic 4‑hydroxymandelic acid synthase (shmaS) in our l‑tyrosine‑overproducing Escherichia coli BKT5. The 
expression level of shmaS was optimized to improve 4‑HMA production by fine tuning of four promoters of differ‑
ent strength combined with three plasmids of different copy number. Furthermore, two genes aspC and tyrB in the 
competitive pathway were deleted to block the formation of byproduct to enhance 4‑HMA biosynthesis. The final 
engineered E. coli strain HMA15 utilized glucose and xylose simultaneously and produced 15.8 g/L of 4‑HMA by fed‑
batch fermentation in 60 h.
Conclusions: Metabolically engineered E. coli strain for 4‑HMA production was designed and constructed, and effi‑
ciently co‑fermented glucose and xylose, the major components in the hydrolysate mixture of agricultural biomass. 
Our research provided a promising biomanufacturing route to produce 4‑HMA from lignocellulosic biomass.
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Background
4-Hydroxymandelic acid (4-HMA) is widely used in pro-
duction of aromatic drugs and flavors. It is employed for 
the preparation of 4-hydroxyphenylacetic acid, which is 
the synthetic precursor of selective β1-receptor antago-
nist drug atenolol [1]. 4-HMA can conjugate cytotoxic 
drug and enzyme substrate, and such a 4-HMA based 
adaptor system showed promising application in the 
targeting drug delivery system [2]. Moreover, 4-HMA 
derivatives, polyhydroxylated mandelic acid amides, 
were reported with higher radical scavenging activities 
than that of antioxidants α-tocopherol and butylated 
hydroxytoluene [3]. Recently, the recombinant Escheri-
chia coli converted 3-ethoxy-4-HMA to ethyl vanillin, a 
widely used flavor in foods, beverages and cosmetics [4].
4-HMA is currently synthesized by condensation 
of glyoxylic acid with excessive phenol via chemical 
approach [5], which is facing many challenges. First, 
feedstock like phenol origins from fossil energy as coal, 
which is unsustainable. Second, condensation reaction 
with sodium or potassium hydroxide is extremely envi-
ronmentally unfriendly, and causes pollution in its pro-
duction and refinery. Third, subsequent acidification of 
the reaction and extraction of excessive phenol make 
downstream process more complicated. At last, such a 
process produces a mixture including byproduct ortho-
isomer 2-hydroxymandelic acid, which is very difficult to 
separate from 4-HMA. Biotechnological approach would 
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be an attractive alternative for 4-HMA production from 
renewable and sustainable bioresources.
4-Hydroxyphenylglycine, 4-HMA derivative, is a nat-
ural building block for several nonribosomal peptide 
antibiotics like chloroeremomycin [6] and vancomycin 
[7]. A gene involved in the biosynthesis of 4-hydroxy-
phenylglycine was identified to encode 4-hydroxyman-
delate synthase (HmaS), which catalyzes the conversion 
of 4-hydroxyphenylpyruvate (4-HPP) to 4-HMA via the 
oxidative decarboxylation reaction and adds hydroxyl to 
the side chain rather than the aromatic ring. Natural phe-
nolic products are derived from aromatic amino acid bio-
synthetic pathway [8], and 4-HPP is the direct precursor 
of l-tyrosine. In the last few years, notable advances have 
been achieved in microbial production of 4-HPP deriva-
tives, such as caffeic acid, L-dopa, 4-hydroxystyrene, phe-
nol, salvianic acid A and flavonoid [9–14].
We previously constructed an E. coli strain BKT5 capa-
ble of overproducing l-tyrosine by deleting five genes 
(ΔptsG, ΔpykA, ΔpykF, ΔtyrR and ΔpheA), and overex-
pressing aroGfbr-tyrAfbr-aroE and glk-tktA-ppsA [13]. In 
this study, we used BKT5 as the starting strain, and the 
gene shmaS of Amycolatopsis orientalis with optimized 
codons was introduced for 4-HMA production (Fig.  1). 
By using the strategy of synthetic biology [15] to improve 
4-HMA biosynthesis, we finely tuned the expression of 
synthetic shmaS gene by combining promoters (as gap, 
lacUV5, trc and T7) of various strengths and vectors of 
various replication origins (as p15A, CloDF13, RSF1030). 
To further enhance metabolic flux to 4-HMA, we manip-
ulated the genome of E. coli BAK5 by deletion of tyrB 
and aspC, which would block the competitive pathway 
from 4-HPP to formation of l-tyrosine. The final engi-
neered E. coli strain HMA15 was employed to produce 
4-HMA using glucose and xylose by fed-batch fermenta-
tion. To our knowledge, this is the first report describing 
engineered E. coli for producing 4-HMA using glucose–
xylose mixture.
Methods
Strains, plasmids, primers and reagents
Strains, plasmids and primers used in this study are listed 
in Tables 1, 2 and 3, respectively. E. coli BW25113 deriva-
tives were used to construct 4-HMA producing strains. 
All chemical reagents were purchased from Sigma 
Aldrich (Beijing, China). Plasmids were isolated using 
the Tianprep Mini plasmid Kit purchased from Tiangen 
(Beijing, China). DNA Gel Extraction Kit from Tiangen 
Fig. 1 The construction process of recombinant expression vectors and engineered pathway for 4‑HMA production. PPP pentose phosphate 
pathway, 6‑P‑G 6‑phosphate‑glucose, 6‑P‑F 6‑phosphate‑fructose, PEP phosphoenolpyruvate, E4P erythrose‑4‑phosphate, DAHP 3‑deoxy‑D‑
arabino‑heptulosonate‑7‑phosphate, DHS 3‑dehydroshikimic acid, SHK shikimic acid, CHA chorismic acid, 4‑HPP 4‑hydroxyphenylpyruvic acid, L‑Phe 
l‑phenylalanine; L‑Tyr l‑tyrosine;4‑HMA 4‑hydroxymandelic acid, TyrR‑tyr TyrR‑tyrosine DNA‑binding transcriptional repressor
Page 3 of 11Li et al. Microb Cell Fact  (2016) 15:90 
was used to isolate DNA fragments from agarose gels. 
All PCR fragments were validated via DNA sequencing 
provided by BGI. Oligonucleotides and synthetic long 
DNA fragments were ordered from GenScript (Nan-
jing, China). DNA polymerase Fastpfu and Taq for PCR 
was purchased from TransGen Biotech (Beijing, China). 
All restriction enzymes and rapid DNA ligase were pur-
chased from Thermo Scientific (Beijing, China). E. coli 
DH5α competent cells were used for the propagation of 
recombinant plasmids.
Codon optimization and assembly of synthetic hmaS gene
Starting from amino acid sequence of HmaS (GenBank 
ID CAA11761.1) of Amycolatopsis orientalis, we opti-
mized the codon usage for hmaS heterologous expression 
in E. coli using a design procedure JCat, and Shine–
Dalgarno-like ribosomal pause sequences and selected 
restriction enzyme recognition sites were also removed. 
Then, the full DNA sequence of hmaS was divided into 
twenty-six oligonucleotides for each one about 60  bp 
long with 20 bp region homologous to its adjacent oligo-
nucleotides. The full length of the hmaS gene was divided 
into two fragments and assembled by two-step overlap-
ping PCR. The 5′-terminal and 3′-terminal fragments of 
the hmaS gene optimized were assembled by first-step 
overlapping PCR with the first fourteen and the latter 
fourteen oligonucleotides, respectively. PCR reaction 
system contained fourteen oligonucleotides each with 
0.2  μM, 0.2  mM dNTPs, 2.5  units TransFast pfu DNA 
polymerase, 1× TransFast pfu buffer in the final volume 
of 50  μL, and 30 cycles of 95  °C for 5  s, 55  °C for 15  s, 
72 °C for 15 s were carried out for PCR amplification pro-
gram. Then the full-length of the hmaS gene was ampli-
fied by the second-step overlapping PCR using these two 
overlapped fragments with the first and last oligonucleo-
tide primers. Synthetic hmaS gene determined to be cor-
rect by sequencing was designated as shmaS, and cloned 
into vector pEASYBlunt, resulting pEBM. The shmaS 
gene was cloned into expression vector pET28a under 
control of T7 promoter, resulting pHMA.
Combinatorial construction of shmaS‑regulated expression 
vectors
In order to screen superior promoter-copy number com-
binations for 4-HMA producing, four promoters Pgap, 
Ptrc, PlacUV5 and PT7 with various expression strength and 
three types of vectors with various copy number (p15A, 
CloDF13, and RSF1030 as replicon) were selected, and 
eleven expression vectors were constructed as shown in 
Table 1 Strains used in this study
Strains Characteristics Source
BAK5 E. coli BW25113 ∆ptsG, ∆tyrR, ∆pykA, pykF, ∆pheA [13]
BAK6 BAK5 ∆tyrB [13]
BAK7 BAK6 ∆aspC This study
BKT5 BAK5 with pYBT5 [13]
BKT6 BAK6 with pYBT5 This study
BKT7 BAK7 with pYBT5 This study
HMA E. coli BL21(DE3) with pHMA This study
HMA01 BKT5 with pAHM1 This study
HMA02 BKT5 with pAHM2 This study
HMA03 BKT5 with pAHM3 This study
HMA04 BKT5 with pAHM4 and pYBH1 This study
HMA05 BKT5 with pCHM1 This study
HMA06 BKT5 with pCHM2 This study
HMA07 BKT5 with pCHM3 This study
HMA08 BKT5 with pCHM4 and pYBH1 This study
HMA09 BKT5 with pRHM1 This study
HMA10 BKT5 with pRHM2 This study
HMA11 BKT5 with pRHM3 This study
HMA12 BKT6 with pCHM3 This study
HMA13 BKT6 with pRHM1 This study
HMA14 BKT6 with pRHM3 This study
HMA15 BKT7 with pCHM3 This study
HMA16 BKT7 with pRHM1 This study
HMA17 BKT7 with pRHM3 This study
Table 2 Plasmids used in this study
Plasmids Characteristics Source
pBldgbrick1 pMB1 ori with PlacUV5 and Ptrc; Ap
R [13]




pYBH1 pYSC1 with PlacUV5 T7 RNA polymerase [13]
pEBM pEASY‑Blunt with shmaS; pUC ori; KanR This study
pHMA pET28a with shmaS This study
pACYCDuet‑1 p15A ori; CmR Novagen
pCDFDuet‑1 CloDF13 ori; StrR Novagen
pRSFDuet‑1 RSF1030 ori; KanR Novagen
pAHM p15A ori; CmR This study
pCHM CloDF13 ori; StrR This study
pRHM RSF1030 ori; KanR This study
pAHM1 pAHM with Pgap‑shmaS This study
pAHM2 pAHM with PlacUV5‑shmaS This study
pAHM3 pAHM with Ptrc‑shmaS This study
pAHM4 pACYCDuet‑1 with PT7‑shmaS This study
pCHM1 pCHM with Pgap‑shmaS This study
pCHM2 pCHM with PlacUV5‑shmaS This study
pCHM3 pCHM with Ptrc‑shmaS This study
pCHM4 pCDFDuet‑1 with PT7‑ shmaS This study
pRHM1 pRHM with Pgap‑shmaS This study
pRHM2 pRHM with PlacUV5‑shmaS This study
pRHM3 pRHM with Ptrc‑shmaS This study
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Table 2. The skeleton vectors pAHM, pCHM and pRHM 
without lacI were obtained by PCR with pACYCDuet-1, 
pCDFDuet-1 and pRSFDuet-1 as templates, respectively.
For the construction of pAHM1, pCHM1 and pRHM1, 
the shmaS gene was amplified from pEBM by PCR with 
primers gapF1 and gapR1. Promoter gap was cloned 
from genome of E. coli BW25113 with primers gapF2 and 
gapR2. The shmaS gene and promoter gap were spliced 
by overlapping extension PCR, constructing Pgap-shmaS, 
which was then ligated at the restriction sites HindIII and 
BamHI of skeleton vectors pAHM, pCHM and pRHM, 
respectively. For the construction of pAHM2, pCHM2 
and pRHM2, the shmaS gene was amplified from pEBM 
with primers lacUV5F1 and lacUV5R1, which was then 
cloned into pBldgBrick1 obtaining recombinant, and 
with it as template, lacUV5F2 and lacUV5R2 as prim-
ers yielding PlacUV5-shmaS, which was then cloned into 
the skeleton vectors pAHM, pCHM and pRHM, respec-
tively. The same method was used for construction of 
pAHM3, pCHM3 and pRHM3. For the construction 
of pAHM4 and pCHM4, the shmaS gene was amplified 
from pEBM by PCR with primers T7F and T7R, which 
was then cloned into the restriction sites NdeI and KpnI 
of pACYCDuet-1 and pCDFDuet-1, respectively, under 
the regulation of T7 promoter directly. Due to the same 
antibiotic resistance of pRHM and pYBH (for expression 
of T7 RNA polymerase), the expression vector pRHM4 
with combination of PT7-shmaS and the skeleton vector 
pRHM was not constructed.
Genome modification and construction of recombinant 
strains
E. coli BAK5 was used as the starting strain, in which five 
genes involved in glucose transportation and l-tyrosine 
biosynthetic pathway had been deleted [13]. Strain BAK6 
was constructed in our previous study [13]. Strain BAK7 
was constructed by further deletion of the aspC gene 
in strain BAK6 using the classical λ-red recombination 
method [16]. Template pKD3 and primers aspCF and 
aspCR were used to clone the fragment for replacing 
the aspC gene with a chloramphenicol resistant selecta-
ble marker. Primers aspCVF and aspCVR were used to 
verify the positive knock-out strain and aspCYZF and 
aspCYZR to verify the final selectable marker removed 
strain. Stains BKT5, BKT6 and BKT7 were constructed 
by transformation of pYBT5 into strain BAK5, BAK6 
and BAK7, respectively. Then transformation of different 
recombinant plasmids constructed in Table 2 into strains 
BKT5, BKT6 or BKT7 contributed to shmaS heterolo-
gous expression strains as characterized in Table 1.
Fermentation media and cultivation conditions
LB medium was used for cultivating the general strains 
for cloning or preparation of fermentation seeds. The 
fermentation of engineered E. coli strain was operated 
at 37  °C and 220  rpm with 50  mL medium in 250  mL 
shake flasks with synthetic minimal salt medium. The 
salt medium contains 17.1 g/L Na2HPO4·12H2O, 3.0 g/L 
KH2PO4, 0.5  g/L NaCl, 3.0  g/L NH4Cl, 0.2  g/L l-phe-
nylalanine, 3.0 g/L l-aspartic acid, 1.0 g/L yeast extract, 
1.0  g/L MgSO4·7H2O, 0.03  g/L CaCl2·2H2O, 0.02  g/L 
FeSO4·7H2O. The initial medium pH was adjusted to 7.0 
by the addition of 10  M NaOH. Sole glucose (4.0  g/L), 
xylose (4.0  g/L), or mixture of glucose (2.0  g/L) and 
xylose (2.0 g/L) were added as carbon source supply. For 
shmaS expression controlled by promoter T7, the prelim-
inary experiments showed that IPTG induction inhibited 
cell growth, and shmaS was expressed without additional 
inducer IPTG in the fermentation process. For shmaS 
expressions controlled by the promoters gap, trc and 
lacUV5, they were constitutively expressed throughout 
the fermentation.
For bioreactor fermentation, the 5 L fermenter (Bailun, 
Shanghai) was employed, and contained 2  L the same 
medium as described in shake flask except for initial 
5.0 g/L glucose, 5.0 g/L xylose and 5.0 g/L yeast extract. 
300  ml seed culture was inoculated into the bioreac-
tor, yielding an initial OD600 of ~0.3. The dissolved oxy-
gen (DO) level was maintained at 30 % (v/v) by flowing 
2 L/min of air with automatically changing the agitation 
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speed from 300 to 700  rpm. The feeding solution con-
tained 250  g/L glucose, 250  g/L xylose, 60  g/L yeast 
extract, 3.0  g/L l-aspartate, 0.2  g/L l-phenylalanine. 
The speed of feeding was regulated to keep the concen-
tration of residual sugars at appropriate level. Fed-batch 
fermentation was performed twice and average data were 
shown.
Broth samples were withdrawn periodically to deter-
mine the cell biomass, concentrations of residual sugars 
and metabolites produced. Each fermentation was con-
ducted in triplicates. Antibiotics were supplemented to 
the media when needed at the following concentrations: 
50 mg/L ampicillin, 30 mg/L kanamycin, 30 mg/L strep-
tomycin, 20 mg/L chloramphenicol.
Analytical methods
Cell growth was monitored by measuring the absorbance 
at 600  nm (OD600) using an UV–VIS spectrophotom-
eter. Glucose consumption was quantified by a biosensor 
SBA-90 (Biology Institute of Shandong Academy of Sci-
ences, China). Residual concentration of xylose was meas-
ured using Waters 1515 HPLC system, equipped with a 
Bio-Rad HPX-87H column and a refractive index detector 
(Waters 2414, Milford, USA), and the column was eluted 
at 65 °C with 5 mM sulfuric acid at 0.6 mL/min.
The broth samples were centrifuged, and supernatants 
were filtered through 0.22 μm syringe filter, and injected 
to the HPLC system. 4-HMA and l-tyrosine were meas-
ured using Agilent 1200 HPLC system equipped with a 
C18 column (250 × 4.6 mm, Agilent) and a PDA detec-
tor (Agilent) at 196 nm with a mobile phase (10 % metha-
nol-90 % H2O, addition of 0.1 % formic acid) at 1.0 mL/
min. The structure of 4-HMA was identified using LC–
MS (Agilent 1200 HPLC system and 6310 Ion Trap mass 
spectrum system, Agilent) under negative ion mode. All 
of the HPLC analysis were quantified using a six point 
standard curve and the R2 coefficient for the standard 
curve was higher than 0.99.
Fig. 2 HPLC and LC–MS analysis of 4‑HMA produced by shmaS‑expressing strain HMA. a HPLC analysis of standard 4‑HMA. b LC–MS analysis of 
standard 4‑HMA. c Identity of 4‑HMA detected in the fermentation supernatant by HPLC analysis, compared the retention time to standard 4‑HMA. 
d The identity of 4‑HMA detected in the fermentation supernatant by LC–MS analysis, compared m/z to standard 4‑HMA
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Results and discussion
Expression of synthetic shmaS gene with optimized codons 
led to 4‑HMA production
The hmaS gene encodes an α-keto acid-dependent dioxy-
genase in the biosynthesis of polycyclic nonribosomal 
glycopeptide antibiotic chloroeremomycin [6, 7]. It acts 
on phenyl α-keto acid to decarboxylate, and one oxygen 
from molecular oxygen is incorporated into the carbonyl 
group and one into the benzylic hydroxyl group to form 
α-hydroxyl acid [17]. HmaS can catalyze the conversion 
of 4-HPP and phenylpyruvate to 4-HMA and mande-
late, respectively, and the biosynthetic pathways for pro-
duction of D-/L-phenylglycine, and S-/R-mandelic acid 
from phenylpyruvate were constructed in E. coli [18–
20]. Enzymatic activity of A. orientalis HmaS towards 
4-hydroxyphenylpyruvate (4-HPP) was higher than that 
of S. coelicolor HmaS [18]. Thus, we chose hmaS from 
actinomyces A. orientalis to construct a heterologous 
4-HMA biosynthetic pathway in E. coli.
Native hmaS sequence of A. orientalis is character-
ized with high GC content (over 72 %) and not suitable 
to express in E. coli. Optimization of the coding sequence 
of hmaS is necessary for the efficient heterologous 
expression. According to codon usage bias of E. coli, and 
elimination of the secondary structure of its mRNA, we 
designed the full length DNA sequence of hmaS and des-
ignated as shmaS. Full sequence of shmaS was conveni-
ently assembled by overlapping PCR (detailed description 
in “Methods” section). The expression vector pHMA was 
constructed and introduced to strain BL21 (DE3), result-
ing the recombinant strain HMA.
Strain HMA was cultivated in mineral salt medium 
with addition of 0.4  % glucose and 0.5  g/L l-tyrosine. 
After 24 h of cultivation, the supernatant of fermentation 
broth was analyzed by HPLC, and 4-HMA was identified 
by LC–MS analysis. Strain HMA carrying shmaS pro-
duced a major product that has the same retention time 
as standard 4-HMA (Fig. 2a, c) and the identical [M-H]− 
ions to standard 4-HMA (Fig.  2b, d). The primary ion 
fragment at m/z 167 ([M-H]−) (Fig.  2d) corresponds to 
4-HMA with molecular weight of 168. These results con-
firm the functionality of optimized and synthetic shmaS 
gene in the biosynthesis of 4-HMA via its expression in 
E. coli.
We aimed at expanding the aromatic amino acid 
pathway to establish a novel biosynthetic platform 
for the microbial production of 4-HMA. HmaS of the 
4-hydroxyphenylglycine biosynthetic pathway in A. ori-
entalis was characterized to convert 4-HPP to 4-HMA [6] 
by the unusual catalytic mechanism of decarboxylation 
and dioxidation [7]. l-tyrosine biosynthetic pathway pro-
vides precursor 4-HPP [21], which would be converted to 
4-HMA by heterologous expression of synthetic shmaS 
in this study (Fig. 1). Thus we constructed the new meta-
bolic pathway for the production of 4-HMA in E. coli.
Fine tuning of shmaS expression improved 4‑HMA 
production by combination of promoters and copy 
numbers
The expression levels of genes involved in the pathway 
affect the production of enzymes encoded and corre-
sponding products, but the precise artificial regulation 
of a specific gene in a specific host context is hard to 
achieve [22]. Thus strategies trying to tune gene expres-
sion have been developed, among them, promoter engi-
neering [23], and fine tuning by combinatorial regulation 
of promoter strength and copy number [24] displayed 
efficiency for metabolic engineering and synthetic biol-
ogy. Here, we regulated the expression of shmaS gene by 
combining four promoters of various strength (as Pgap, 
PlacUV5, Ptrc, PT7) and three plasmids with various replica-
tion origins (as p15A, CloDF13, RSF1030).
All eleven recombinant E. coli strains expressing 
shmaS on various vectors produced 4-HMA, and their 
titers were largely diverse (Fig.  3a, Additional file  1: 
Table S1). After 24  h of fermentation, strain HMA02 
produced 4-HMA with the lowest titer of 17.15  mg/L, 
while HMA11 produced 4-HMA with the highest titer 
of 160.05 mg/L, and the ratio of the highest to the low-
est 4-HMA titer was 9.3-fold. Obviously, the fine tun-
ing strategy of combinatorial regulation in expression of 
shmaS helped us screen out three higher yielding strains 
HMA07, HMA09 and HMA11, the titers of 4-HMA were 
153.59, 146.68 and 160.05 mg/L, respectively.
Among three types of plasmids, copy numbers with 
replication origin p15A, CloDF13 and RSF1030 are esti-
mated about 10, 30 and 100, respectively [25]. When 
weak promoter lacUV5 drove expression of shmaS on 
the low or high copy number vectors, the lowest titer of 
4-HMA was produced, compared with promoters T7, trc 
and gap. Hybrid promoter trc is popularly used in meta-
bolic engineering [26] and its strength is considered to 
be stronger than that of lacUV5. When the shmaS was 
expressed under the control of promoter trc, the titers 
of 4-HMA were approximately three-fold of increase, 
compared to promoter lacUV5 on middle and high copy-
number vectors. Promoter T7 is well known as a very 
strong promoter, and widely used in production of het-
erologous proteins and metabolic engineering. Herein, 
the expression of shmaS on the middle copy-number vec-
tor under control of promoter T7 could be beneficial for 
production of 4-HMA, but not optimal. Promoter gap 
is a strong constitutive promoter regulating expression 
of glyceraldehyde 3-phosphate dehydrogenase in glyco-
lysis pathway, and ever been used for high production of 
resveratrol [27]. The expression of shmaS driven by the 
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gap promoter on high copy-number vector resulted in 
the production of 4-HMA up to 146.68  mg/L in strain 
HMA09, however promoter gap was lesser efficient to 
express shmaS for 4-HMA production, compared with 
promoter trc on the same vector.
Although fine tuning of shmaS expression through 
combination of promoters and gene copy-numbers 
improved the production of 4-HMA in l-tyrosine over-
producing background strains by using glucose, as shown 
in Fig. 3b (Additional file 1: Table S1), byproduct l-tyros-
ine was unexpectedly accumulated in fermentation broth. 
HmaS can also convert phenylpyruvate to mandelic acid 
[18–20], however, no phenylpyruvate and its derivative 
byproducts were detectable in our pheA deficient strains. 
Incomplete conversion of metabolic intermediate 4-HPP 
to 4-HMA would lead to accumulation of l-tyrosine 
(Fig.  1). It indicated that metabolic flux to l-tyrosine 
could compete the formation of 4-HMA. We speculated 
that blocking the flux from 4-HPP to l-tyrosine might 
further improve the production of 4-HMA.
Genome modification enhanced 4‑HMA production 
by blocking byproduct formation
In order to enhance the production of 4-HMA, a logical 
possibility can be considered by blocking the conversion 
of 4-HPP to l-tyrosine through modifying the genome 
of strain BAK5, which was constructed by deleting ptsG, 
tyrR, pheA, pykA, and pykF in our previous study [13]. 
In E. coli, two aminotransferases are involved in the last 
step of the biosynthesis of l-tyrosine [28]. Under normal 
conditions, the aromatic amino acid aminotransferase 
encoded by tyrB is the main enzyme for l-tyrosine bio-
synthesis from 4-HPP. In case of higher 4-HPP pool, the 
aspartate aminotransferase encoded by aspC could con-
tribute to the biosynthesis of l-tyrosine as well. In order 
to verify our hypothesis, sequentially inactivating the 
tyrB and aspC genes from the l-tyrosine biosynthetic 
pathway was implemented. We deleted tyrB and aspC in 
strain BAK5 background in sequence by λ-red recom-
binant method and constructed two new strains BAK6 
and BAK7 for expression of shmaS. After introduction 
of pYBT5 (Table  2) and three shmaS expression vectors 
(pCHM3, pRHM1 and pRHM3), resulting engineered 
strains were cultivated for fermentation 4-HMA. 3.0 g/L 
of L-aspartate was added in mineral salt medium to sup-
port growth of strains with aspC deletion.
As expected, for tyrB or/and aspC deletion strains, 
byproduct l-tyrosine was totally undetectable, mean-
while an obvious increase in 4-HMA production was 
observed (Fig.  4), in comparison with the unmodi-
fied strains. Deletion of tyrB led to 1.45-fold increase of 
4-HMA titer of 376.26 mg/L in strain HMA12 (pCHM3) 
at 24  h fermentation. Further deletion of aspC contrib-
uted to improvement of 4-HMA production, but the 
efficacy depended on the expression vectors of shmaS. 
Compared to expression vectors pRHM1 and pRHM3, 
vector pCHM3 gave the highest titer of 4-HMA produc-
tion in strain BKT7 background with double deletions 
of tyrB and aspC. Strain HMA15 (pCHM3) produced 
594.07  mg/L of 4-HMA, 30.8 and 59.2  % higher than 
strains HMA16 (pRHM1) and HMA17 (pRHM3), 
respectively.
Fig. 3 Fine tuning of shmaS expression by combinatorial regulation for screening 4‑HMA high‑yielding strains at 24 h of fermentation. a 4‑HMA 
production. b l‑tyrosine accumulation
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TyrB and AspC are identified as isoenzymes [29] and 
also involved in biosynthesis of l-phenylalanine [30]. In 
previous reports, tyrB and aspC were deleted to block the 
biosynthesis of l-phenylalanine, and titers of phenylpyru-
vate [31] and its derivatives R-/S-mandelic acid [19], 
d-/l-phenylglycine [18, 20] and benzyl alcohol [32] were 
greatly improved. In this study, deletion of tyrB and aspC 
completely blocked the formation of byproduct l-tyros-
ine from precursor 4-HPP and resulted in significant 
increase of 4-HMA production. Therefore, double dele-
tions of tyrB and aspC could benefit for the fermenta-
tive production of aromatic 4-HMA from 4-HPP and its 
analogs, mandelic acid, phenylglycine and benzyl alcohol 
from phenylpyruvate.
Fed‑batch fermentation for production of 4‑HMA 
by co‑utilization of xylose and glucose
Lignocellulosic biomass is the most abundant biore-
source in nature, utilization of lignocellulose hydrolysate 
in fermentation industry for the production of fine chem-
icals and biofuels is very promising [33]. However, simul-
taneous utilization of glucose and xylose in lignocellulose 
hydrolysate is still a challenge, because E. coli metabo-
lizes glucose in preference to other sugars [34]. As shown 
in Fig.  5a, carbon catabolite repression (CCR) by glu-
cose was obvious in the wild type E. coli BW25113, and 
sequential consumption of carbon sources was evident. 
When cultivated with glucose or xylose as the sole car-
bon source, the wild type BW25113 consumed glucose 
faster than xylose. However, when glucose and xylose 
mixture was provided, the wild type BW25113 consumed 
glucose rapidly while xylose was used after glucose was 
significantly depleted.
To release glucose repression, phosphoenolpyruvate-
carbohydrate phosphotransferase system (PTS) was often 
focused as an important target of genetic modification 
[35]. The ptsG gene is responsible for transportation of 
glucose into cytoplasm and deleted in strain HMA15 
(Table  1). Thus fermentation of 4-HMA in ptsG defi-
cient strain HMA15 was comparatively carried out in 
shake flasks by three fed-batch modes, glucose or/and 
xylose used as sole or mixed carbon source. As shown 
in Fig. 5b, when glucose was used as sole carbon source, 
strain HMA15 produced 601.56  mg/L of 4-HMA at 
24  h fermentation. With additional amount of glucose 
fed, the titer of 4-HMA was continuingly increased to 
747.13 mg/L at 48 h. When sole xylose was fed as carbon 
source, strain HMA15 produced 820.18 mg/L of 4-HMA, 
slightly higher than fed with glucose at 48  h (Fig.  5c). 
Furthermore, Fermentation was carried out by feed-
ing glucose–xylose mixture. Different ratios of glucose 
and xylose as carbon source showed that sugar mixture 
of glucose (2.0 g/L) and xylose (2.0 g/L) at equal amount 
resulted in the highest titer of 4-HMA at 48  h fermen-
tation (Additional file  1: Figure S1). When equal mass 
amounts of both glucose and xylose were fed as mixed 
carbon source, strain HMA15 produced 1.11  g/L of 
4-HMA (Fig. 5d), displaying 48.6 and 35.3 % higher than 
that fed with glucose and xylose, respectively.
Feeding fermentation of strain HMA15 was further 
performed for production of 4-HMA in 5 L bioreactor. 
Feeding solution was added into the bioreactor based 
on concentration of residual sugars to maintain it lower 
than 2.0 g/L. In all, 42.5 g/L glucose and 42.5 g/L xylose 
were consumed in bioreactor fermentation. The produc-
tion of 4-HMA showed a cell growth-dependent manner 
(Fig. 6). The maximum cell density (OD600) was ~34.0 at 
60 h, and 4-HMA titer was 15.8 g/L with a productivity of 
0.26 g/L h−1. During the fermentation, byproduct acetate 
(3.4 g/L) was detected. It might be caused by the overflux 
of sugar metabolism. Reduction of acetate accumulation 
[36] would further improve the yield and titer of 4-HMA.
E. coli utilizes xylose as a secondary sugar by the gen-
eral control of CCR. PTS is the most efficient system 
for transporting sugars, and plays a crucial role in CCR. 
PEP-dependent glucose-specific PTS is composed of 
four components including the soluble non-sugar-spe-
cific enzymes EI and HPr (encoded by ptsI and ptsH, 
respectively), and glucose-specific soluble enzyme EIIA 
(encoded by crr) and membrane-integral permease EIICB 
(encoded by ptsG). Inactivating one of the PTS compo-
nents could abolish CCR in E. coli, and the effects of dif-
ferent CCR-insensitive mutants on cell growth and sugar 
consumption were varied, which showed different appli-
cation for production of various products [37]. Here we 
showed that ptsG negative strain HMA15 simultaneously 
utilized glucose and xylose (Fig. 5d). It was consistent to 
previous studies when equal mass of glucose–xylose mix-
ture was employed [38, 39]. In E. coli without ptsG, GalP 
Fig. 4 Titers of 4‑HMA produced by genome modification through 
deleting tyrB and aspC at 24 h fermentation
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and MglABC are involved in glucose transport, but they 
are less effective than PtsG [40]. In addition, pykF- and 
pykA-deficiency in strain HMA15 might lead to slow 
glucose metabolism as corresponding pyruvate kinase 
catalyze formation of pyruvate and release energy ATP 
for glucose phosphorylation and cell growth. When the 
CCR was abolished, xylose could be transported via non-
PTS XylE and XylFGH [34] and catabolized via pentose 
phosphate pathway (PPP). Furthermore, overexpression 
of tktA coding transketolase A in strain HMA15 would 
enhanced xylose metabolism and benefit to the forma-
tion of precursor E4P for aromatic compound production 
[41]. Meanwhile, inactivation of ptsG, pykF and pykA in 
strain HMA15 would increase carbon flux from glucose 
to PEP via glycolysis, which is precursor for aromatic 
compound biosynthesis (Fig. 1). Taking together, co-uti-
lization of glucose and xylose would further promote the 
production of aromatic 4-HMA in strain HMA15.
Recently, several alternative strategies have been pro-
posed to achieve co-utilization of glucose and xylose in 
E. coli. Constitutive expression of xylose metabolism 
was required from the araC mutant strain by adaptive 
evolution in xylose minimal medium, which showed 
the simultaneous co-utilization of glucose and xylose 
and possessed the same growth pattern as the wild type 
[39]. Similarly, growth adaptation of ptsG deficient E. 
coli strain on arabinose resulted in the simultaneous 
Fig. 5 4‑HMA production, cell growth and sugar consumption in shake flasks. a Consumption of sole sugar and sugars mixture of the wild type 
E. coli BW25113. b Fed‑batch fermentation of HMA15 with sole glucose as carbon source. c Fed‑batch fermentation of HMA15 with sole xylose as 
carbon source. d Fed‑batch fermentation of HMA15 with mixture of glucose and xylose as carbon sources
Fig. 6 Fed‑batch fermentation of HMA15 with glucose–xylose 
mixture in 5 L bioreactor
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utilization of glucose, xylose and arabinose [42] and was 
used to produce 3-hydroxybutyric acid [43]. By using 
SIMUP algorithm, growth phenotype of E. coli was pre-
dicted; co-utilization of glucose and xylose was con-
structed by deleting pgi, rpe and eda [44]. It is the first 
report to achieve co-utilization of two sugars without 
targeting the regulatory pathways of CCR. Protein engi-
neering of the hexose- or pentose- specific transporters 
might be orthogonal strategy to confer the co-utilization 
of glucose and xylose [45, 46].
Conclusions
Biosynthesis of 4-HMA was achieved through heterolo-
gous expression of fully synthetic shmaS gene in E. coli. 
Expression of shmaS was optimized to improve produc-
tion of 4-HMA by combinatorial regulation with various 
promoters and copy numbers. Production of 4-HMA was 
further increased by deletion of tyrB and aspC on E. coli 
genome to block the formation of byproduct l-tyrosine. 
Furthermore, fed-batch fermentation mode with both 
sugars showed that engineered strain can utilize xylose 
and glucose simultaneously, and glucose–xylose mixture 
gave high production of 4-HMA with the titer of 15.8 g/L 
at 60 h fermentation in 5 L bioreactor. It is expected that 
4-HMA production would be further improved through 
control of acetate biosynthesis and optimization of the 
fermentation process. Co-utilization of glucose and 
xylose will be promising for the production of other aro-
matic products of interest.
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